Navigation Links
Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Date:8/19/2007

(10,284) (17,599) (20,516) (105,117)

Other income

(expenses):

Interest income 448 1,060 686 1,753 4,560

Interest expense (74) (86) (125) (179) (1,261)

Change in fair

value of warrant

Liability 471 (86) 127 (149) (454)

Other expense 2 - (1) - (1,181)

Loss before

tax benefit (8,624) (9,396) (16,912) (19,091) (103,453)

Income tax benefit - - - - 695

Net loss (8,624) (9,396) (16,912) (19,091) (102,758)

Deemed dividend (19,424) - (19,424) - (19,424)

Preferred stock

accretion (41) (310) (81) (351) (802)

Net loss

attributable

to common

stockholders $(28,089) $(9,706) $(36,417) $(19,442) $(122,984)

Net loss

attributable

to common

stockholders per

common share --

basic and diluted $(39.04) $(1.37) $(57.78) $(4.80)

Weighted-average

common shares

outstanding --

basic and

diluted 719,556 7,083,748 630,230 4,051,709

See accompanying notes to consolidated financial statements

Amicus Therapeutics, Inc

Statement of Operations Information for 3 months ending June 30, 2007

Change in

Fair

Value of Preferred Stock

Warrant Stock Compen- GAAP as

Non-GAAP Liability Accretion sation Reported

Income Statement

Classifications:

Research and development (6,361)
'/>"/>

SOURCE Amicus Therapeutics

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amicus Therapeutics Presents Positive Results From Phase 1 Clinical Studies of Plicera for Gaucher Disease
2. Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease
3. Amicus Therapeutics Presents Data From Preclinical and Phase 1 Studies of Amigal for Fabry Disease
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
8. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
9. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
10. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
11. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014 Pomerantz LLP is investigating ... ("PDL BioPharma" or the "Company") (NASDAQ: PDLI).  Such investors ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... of its officers and/or directors have violated Sections 10(b) ... On September 17, 2014, the Company ...
(Date:9/17/2014)... 17, 2014  Rebiotix Inc. announced this morning that results ... candidate, RBX2660 (microbiota suspension) will be presented in two posters ... Philadelphia from October 8-12. ... poster session on Thursday, October 9, 2014: Poster: ... 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study ...
(Date:9/17/2014)... , Sept. 17, 2014  Bayer HealthCare will present ... Foundation,s 66 th Annual Meeting, which takes place ... The data, which will be shared through poster presentations, ... patient care. Data will be presented in a scientific ... treatment modalities in hemophilia A patients, Bayer is maintaining ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PDL BioPharma, Inc. - PDLI 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4
...   , Strategic collaboration with Ipsen for marketing ... Nordics and the US , Photocure to commercialise ... Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on ... of a new commercial strategy for Hexvix, its flagship product ...
... Luminex Corporation (NASDAQ: LMNX ), today ... its annual European multiplexing technology symposium, September 28-29, 2011, ... feature scientific sessions, workshops, discussion groups, exhibitions and networking ... who are performing groundbreaking work in clinical diagnostics and ...
Cached Medicine Technology:Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 2Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 3Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 4Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 5Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 6Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 7Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 8Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna 2Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna 3Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna 4
(Date:9/17/2014)... 2014 People who struggle to distinguish between ... http://www.perwickstrom.com and get the answer by reading Per ... out, is that a business plan and a business strategy ... commented Per Wickstrom. “The way I view it is that ... strategy which is part two.” , According to the ...
(Date:9/17/2014)... damage to the ends of chromosomes could hold the key ... form of skin cancer according to new research from ... an important new genetic risk factor for melanoma. , It ... strongest indicators of those most at risk of developing melanoma. ... sun, as they burn more easily. , It now appears ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 North Central ... recently granted several awards for their top-notch services. The ... experience, orthopedic care and GYN surgery. , Hospital-wide, North ... Excellence Award™. They have received this award for two ... the top 5 percent in the nation for Patient ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Tidewater ... host recruit757’s scholarship workshop for football players and their ... Sept. 23. , Doors open at 6:30 p.m. for ... and speak to trainers and physical therapists. The workshop ... p.m. , The Newport News Tidewater Performance Center, which ...
(Date:9/17/2014)... News) -- Positive messages about the health benefits of ... a new study suggests. Although smokers who think ... about the harmful effects of smoking, researchers found smokers ... more from "gain-framed," or positive, messages about how quitting ... using a mix of both types of messages might ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:Chromosome buffers hold key to better melanoma understanding 2Health News:North Central Surgical Center Receives Several Accolades 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 3Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2
... Washingtonian ... ... was identified as a "Top Therapist" in the July 2009 issue of Washingtonian ... playing in the Washington, DC, area for more than four decades thanks to features like ...
... ... supplier of industrial and technical parts and free CAD images to engineers, ... customers. John Carrier, the company,s President, says the new ReidSupply.com is all about ... on marketing. The new site takes the customer exactly where they want to ...
... LONDON, July 7 Frost & Sullivan has conferred ... (VWS). The "2008 Frost & Sullivan European Pharmaceutical Water ... VWS for its successful strategies that have enabled it ... process water and wastewater solution providers for the pharmaceutical ...
... OAK BROOK, Ill. (July 7, 2009) Using magnetic resonance ... and accurately locate lesions prior to surgery, according to a ... . "Pelvic MRI at 3 Tesla is a ... said the study,s lead author, Nathalie Hottat, M.D., from the ...
... SMOKING CESSATION MAY PROVIDE IMMEDIATE BENEFIT TO HEART ... provides immediate benefits to patients. Researchers from the ... examined specific inflammatory biomarkers associated with cardiovascular disease ... cessation process. Results showed that smoking cessation resulted ...
... Sonitus Medical, Inc., a medical device company developing the ... sound via the teeth, today announced the acceptance for ... SoundBite(TM) hearing system. The article, featuring a preliminary evaluation ... in an upcoming issue of the esteemed Otology ...
Cached Medicine News:Health News:Karen J. Osterle Recognized as a Top Psychotherapist in Washingtonian Magazine 2Health News:Customers Design Reid Supply's New Web Site 2Health News:Customers Design Reid Supply's New Web Site 3Health News:Customers Design Reid Supply's New Web Site 4Health News:Customers Design Reid Supply's New Web Site 5Health News:Dual Frost & Sullivan Accolade for Veolia Water Solutions & Technologies 2Health News:Dual Frost & Sullivan Accolade for Veolia Water Solutions & Technologies 3Health News:Dual Frost & Sullivan Accolade for Veolia Water Solutions & Technologies 4Health News:Dual Frost & Sullivan Accolade for Veolia Water Solutions & Technologies 5Health News:MRI accurately depicts deep endometriosis 2Health News:News briefs from the July issue of CHEST 2Health News:SoundBite(TM) Hearing System by Sonitus Medical Receives First Acceptance for Publication in Otology & Neurotology Journal 2Health News:SoundBite(TM) Hearing System by Sonitus Medical Receives First Acceptance for Publication in Otology & Neurotology Journal 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: